Measurement of plasma microRNA-500 could differentiate between liver fibrosis and cirrhosis
El-Ashmawy, N., Al-Ashmawy, G., Zayed, L., Hassan, A., Soliman, R., Shiha, G. (2021). Measurement of plasma microRNA-500 could differentiate between liver fibrosis and cirrhosis. EKB Journal Management System, 5(2), 133-142. doi: 10.21608/jcbr.2020.39544.1062
Nahla El-Ashmawy; Ghada Al-Ashmawy; Linda Zayed; Ayman Hassan; Reham Soliman; Gamal Shiha. "Measurement of plasma microRNA-500 could differentiate between liver fibrosis and cirrhosis". EKB Journal Management System, 5, 2, 2021, 133-142. doi: 10.21608/jcbr.2020.39544.1062
El-Ashmawy, N., Al-Ashmawy, G., Zayed, L., Hassan, A., Soliman, R., Shiha, G. (2021). 'Measurement of plasma microRNA-500 could differentiate between liver fibrosis and cirrhosis', EKB Journal Management System, 5(2), pp. 133-142. doi: 10.21608/jcbr.2020.39544.1062
El-Ashmawy, N., Al-Ashmawy, G., Zayed, L., Hassan, A., Soliman, R., Shiha, G. Measurement of plasma microRNA-500 could differentiate between liver fibrosis and cirrhosis. EKB Journal Management System, 2021; 5(2): 133-142. doi: 10.21608/jcbr.2020.39544.1062

Measurement of plasma microRNA-500 could differentiate between liver fibrosis and cirrhosis

Egyptian Journal of Cancer and Biomedical Research
Article 12, Volume 5, Issue 2, June 2021, Page 133-142  XML PDF (2.65 MB)
Document Type: Original Article
DOI: 10.21608/jcbr.2020.39544.1062
View on SCiNiTO View on SCiNiTO
Authors
Nahla El-Ashmawy1; Ghada Al-Ashmawy email orcid 1; Linda Zayed2; Ayman Hassan3; Reham Soliman4; Gamal Shiha5
1Department of Biochemistry, Faculty of Pharmacy, Tanta University, Tanta, Egypt
2Clinical Trial Unit & Bioequivalence Center, Egyptian Liver Research Institute and Hospital (ELRIAH), Cairo, Egypt
3Molecular Biology Unit, Egyptian Liver Research Institute and Hospital, Cairo, Egypt
4Tropical Medicine Department, Faculty of Medicine, Port Said University. and Egyptian Liver Research Institute and Hospital, Egypt
5Internal Medicine Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt
Abstract
Background: A significant number of patients with hepatitis C virus (HCV) infection are at high risk of progressing to liver cirrhosis and hepatocellular carcinoma (HCC). The lack of noninvasive methods for assessment of the degree of liver damage is the main limitation in the clinical management of liver diseases. Aim: This study was conducted to evaluate the expression level of plasma miR-500 in HCV-induced fibrosis, cirrhosis and HCC patients. Methods and results: This prospective study involved 120 subjects, who were divided into 4 groups (n=30/group): healthy control, liver fibrosis patients, liver cirrhosis patients and HCC patients; all patients encountered in the work were clinically diagnosed as chronic HCV patients. The expression of miR-500 in plasma was asessed using quantitative real-time PCR, whereas serum alpha-fetoprotein (AFP) was measured using electrochemi-luminescence immunoassay. Results: The fold change in expression of plasma miR-500 showed significant up-regulation in cirrhotic patients more than 8 fold change as compared to fibrosis group. No significant fold changes in plasma miR-500 expression were found between either (HCC versus cirrhosis group) or (HCC versus fibrosis group. The serum level of AFP was 28.09 higher in the HCC group than non-HCC group.  Receiver operating characteristic curve (ROC) analysis indicated that the ideal cut-off values of the plasma miR-500 in both fibrosis and cirrhosis groups were 1.52 and 1.15, respectively and 8.2 and 4.55, respectively for AFP. Conclusion: Plasma miR-500 can be used as a novel biomarker for the differentiation between liver fibrosis and cirrhosis.
Keywords
Biomarkers; Hepatocellular carcinoma; Liver cirrhosis; Liver fibrosis; MicroRNA-500
Statistics
Article View: 396
PDF Download: 219